JP2019513370A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513370A5
JP2019513370A5 JP2018551953A JP2018551953A JP2019513370A5 JP 2019513370 A5 JP2019513370 A5 JP 2019513370A5 JP 2018551953 A JP2018551953 A JP 2018551953A JP 2018551953 A JP2018551953 A JP 2018551953A JP 2019513370 A5 JP2019513370 A5 JP 2019513370A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
acid sequence
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018551953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/025573 external-priority patent/WO2017173384A1/en
Publication of JP2019513370A publication Critical patent/JP2019513370A/ja
Publication of JP2019513370A5 publication Critical patent/JP2019513370A5/ja
Pending legal-status Critical Current

Links

JP2018551953A 2016-04-01 2017-03-31 キメラ受容体及びその使用方法 Pending JP2019513370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317068P 2016-04-01 2016-04-01
US62/317,068 2016-04-01
PCT/US2017/025573 WO2017173384A1 (en) 2016-04-01 2017-03-31 Chimeric receptors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020152515A Division JP7134204B2 (ja) 2016-04-01 2020-09-11 キメラ受容体及びその使用方法

Publications (2)

Publication Number Publication Date
JP2019513370A JP2019513370A (ja) 2019-05-30
JP2019513370A5 true JP2019513370A5 (https=) 2019-10-24

Family

ID=59960746

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018551953A Pending JP2019513370A (ja) 2016-04-01 2017-03-31 キメラ受容体及びその使用方法
JP2020152515A Active JP7134204B2 (ja) 2016-04-01 2020-09-11 キメラ受容体及びその使用方法
JP2022136417A Active JP7451627B2 (ja) 2016-04-01 2022-08-30 キメラ受容体及びその使用方法
JP2024033511A Active JP7673272B2 (ja) 2016-04-01 2024-03-06 キメラ受容体及びその使用方法
JP2025071243A Pending JP2025111619A (ja) 2016-04-01 2025-04-23 キメラ受容体及びその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020152515A Active JP7134204B2 (ja) 2016-04-01 2020-09-11 キメラ受容体及びその使用方法
JP2022136417A Active JP7451627B2 (ja) 2016-04-01 2022-08-30 キメラ受容体及びその使用方法
JP2024033511A Active JP7673272B2 (ja) 2016-04-01 2024-03-06 キメラ受容体及びその使用方法
JP2025071243A Pending JP2025111619A (ja) 2016-04-01 2025-04-23 キメラ受容体及びその使用方法

Country Status (33)

Country Link
US (3) US10597456B2 (https=)
EP (2) EP4180449A1 (https=)
JP (5) JP2019513370A (https=)
KR (7) KR20200068750A (https=)
CN (3) CN113150170B (https=)
AR (1) AR108066A1 (https=)
AU (3) AU2017240788B2 (https=)
BR (1) BR112018070260A2 (https=)
CA (2) CA3019650C (https=)
CL (5) CL2018002797A1 (https=)
CO (1) CO2018010547A2 (https=)
CR (2) CR20210084A (https=)
DK (1) DK3436030T3 (https=)
EA (1) EA201891992A1 (https=)
ES (1) ES2930058T3 (https=)
HR (1) HRP20221348T1 (https=)
HU (1) HUE060645T2 (https=)
IL (2) IL262041B2 (https=)
LT (1) LT3436030T (https=)
MA (1) MA43603A1 (https=)
MX (2) MX2018012019A (https=)
MY (1) MY197669A (https=)
PE (3) PE20211418A1 (https=)
PH (1) PH12018502113A1 (https=)
PL (1) PL3436030T3 (https=)
PT (1) PT3436030T (https=)
RS (1) RS63735B1 (https=)
SG (2) SG10201912519VA (https=)
SI (1) SI3436030T1 (https=)
SM (1) SMT202200444T1 (https=)
TW (5) TW201803896A (https=)
UA (2) UA128781C2 (https=)
WO (1) WO2017173384A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
MX2018011788A (es) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CN109414455B (zh) 2016-04-01 2023-01-20 凯德药业股份有限公司 Bcma结合分子及其使用方法
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
PT3436079T (pt) * 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102359766B1 (ko) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201992782A1 (ru) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
WO2019099707A1 (en) * 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
WO2020030979A2 (en) * 2018-08-10 2020-02-13 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
US12534532B2 (en) * 2018-10-26 2026-01-27 Crage Medical Co., Limited CLL1-targeting antibody and application thereof
WO2020180591A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
CA3139319A1 (en) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えad35ベクター及び関連遺伝子治療改善
CA3154389A1 (en) * 2019-09-13 2021-03-18 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting cd371 and uses thereof
CN112500492B (zh) * 2019-09-13 2023-08-04 中国科学院分子细胞科学卓越创新中心 一种嵌合抗原受体及其用途
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CN113980134B (zh) 2020-12-11 2022-05-31 广州百暨基因科技有限公司 抗cll1抗体及其应用
CN113234162B (zh) * 2020-12-24 2022-05-13 四川大学华西医院 一种靶向cd133的嵌合抗原受体t细胞
CN113416713A (zh) * 2021-05-11 2021-09-21 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 一种重组腺病毒的构建及其应用
CN115521917A (zh) * 2021-06-25 2022-12-27 南京北恒生物科技有限公司 工程化免疫细胞及其用途
US20250101104A1 (en) 2022-01-26 2025-03-27 Mabswitch Inc. Bispecific molecule with tunable affinity to a targeted antigen
TW202340457A (zh) * 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
GB202301949D0 (en) 2023-02-10 2023-03-29 Coding Bio Ltd CLL1 and/or CD33 binding molecules
WO2024186695A2 (en) * 2023-03-03 2024-09-12 Trustees Of Boston University Immune cell fusion (icf) and uses thereof
JP2026512487A (ja) * 2023-04-18 2026-04-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Bcmaキメラ抗原受容体及びその使用
WO2025194098A1 (en) 2024-03-14 2025-09-18 Dana-Farber Cancer Institute, Inc. Engineered immune cells expressing chimeric antigen receptors targeting trop2, and methods of using the same
WO2025231376A1 (en) * 2024-05-03 2025-11-06 Kite Pharma, Inc. Chimeric receptors binding to cll-1 and methods of use thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6892139B2 (en) 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
CN101228658B (zh) 2004-09-03 2013-02-06 通用汽车公司 用于燃料电池叠组中的重复单元和非重复单元的对准方法
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
EP2211903A4 (en) * 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CA2780707A1 (en) 2009-11-17 2011-05-26 Basf Plant Science Company Gmbh Plants with increased yield
EP2566886A1 (en) 2010-05-05 2013-03-13 Addex Pharma SA Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
EP3467101A3 (en) 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
AU2012209103B2 (en) 2011-01-26 2015-12-03 Takeda Pharmaceutical Company Limited Methods and compositions for the synthesis of multimerizing agents
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
DE102012204596A1 (de) 2012-03-22 2013-09-26 Ford Global Technologies, Llc Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
SG11201507026WA (en) 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
EP4303232A3 (en) 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
WO2014151960A2 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
US10246505B2 (en) 2013-11-25 2019-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control HIV infection
US20160376375A1 (en) 2013-11-27 2016-12-29 Baylor College Of Medicine CSGP4 - Specific Chimeric Antigen Receptor for Cancer
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドKite Pharma, Inc B細胞悪性腫瘍及び他のがんの治療に有用な自己t細胞を産生する方法、並びにその組成物
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2015158671A1 (en) 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-bcma嵌合抗原受體治療癌症
KR20170037625A (ko) * 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
CA2959428A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CN107002084B (zh) 2014-09-19 2021-09-10 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
BR112017011893A2 (pt) 2014-12-05 2018-07-24 City Of Hope células t modificadas no receptor de antígeno quimérico direcionado para cs1
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
EP3283520B1 (en) 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
PL3988117T3 (pl) 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
CN109414455B (zh) 2016-04-01 2023-01-20 凯德药业股份有限公司 Bcma结合分子及其使用方法
MY210545A (en) 2016-04-01 2025-09-30 Kite Pharma Inc Chimeric receptors to flt3 and methods of use thereof
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법

Similar Documents

Publication Publication Date Title
JP2019513370A5 (https=)
AU2019243665B2 (en) Multivalent antibody
CN111018986B (zh) 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
JP7701911B2 (ja) Ceacam5およびcd3に対する二特異性抗体
JP2022550832A (ja) Cd3を標的とする抗体、二重特異性抗体及びその使用
CA3116294C (en) Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
WO2018108106A1 (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
JP2020508655A5 (https=)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
CN112028996A (zh) 靶向bcma的单域抗体及其用途
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
JP2018522888A5 (https=)
JP2016536322A5 (https=)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2018528786A5 (https=)
KR20230143177A (ko) 신규한 항-cd24 항체
JP2024001073A5 (https=)
IL316226A (en) Anti-ror1 antibody and ror1-targeting engineered cells
JP2024105603A (ja) CARライブラリおよびscFvの製造方法
AU2020400801B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
JP2021529539A5 (https=)
JPWO2022111633A5 (https=)
KR20210046725A (ko) 신규 암 면역요법 항체 조성물
CN119894930A (zh) 一种双特异性抗体及其应用
JPWO2019219064A5 (https=)